In COVID-19 patients, RSAD2 can enhance antiviral and immunomodulatory functions after viral infection, and patients discharged from the emergency department in the current results had lower levels of RSAD2 methylation, possibly related to high RSAD2 expression levels and enhanced antiviral immunity (Zhu et al., 2020). The gene discussed is RSAD2; the disease is viral infectious disease.